For subscribers
Heart benefits of Wegovy extend beyond weight loss, study shows
Sign up now: Get ST's newsletters delivered to your inbox
In their first 20 weeks of taking Wegovy, patients experienced cardiovascular benefits no matter how much weight they lost.
PHOTO: REUTERS
Dani Blum
Follow topic:
NEW YORK - A new analysis of a major clinical trial affirmed that Wegovy, the popular obesity drug, lowers the risk of major heart issues like heart attacks and strokes in some adults, but showed that weight loss could not fully explain the cardiovascular benefits.
How else, exactly, the drug protects the heart remains a mystery.
